Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GST037
MIFTS: 59

Gastroparesis

Categories: Gastrointestinal diseases, Metabolic diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gastroparesis

About this section

MalaCards integrated aliases for Gastroparesis:

Name: Gastroparesis 12 54 30 56 45 15 17 74
Delayed Gastric Emptying 54
Gastroparesis Syndrome 12
Gastroparalysis 12
Gastric Atonia 12

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases
Anatomical: Gastrointestinal diseases Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:11914
ICD9CM 36 536.3
MeSH 45 D018589
NCIt 51 C80512
SNOMED-CT 69 77164002
ICD10 34 K31.84
UMLS 74 C0152020
Sources

Summaries for Gastroparesis

About this section
NIH Rare Diseases : 54 Gastroparesis, or delayed gastric emptying, is a disorder where the food does not move or moves very slowly from the stomach to the small intestine. In gastroparesis,  the muscles of the stomach do not work well and digestion takes an abnormally long time. Symptoms of gastroparesis include bloating, nausea, vomiting, weight loss due to poor absorption of nutrients, early fullness while eating meals, heartburn, and abdominal pain. Complications can occur including dehydration, electrolyte abnormalities, blood sugar abnormalities, malnutrition, vitamin deficiencies, stomach ulcers, gastroesophageal reflux, esophagitis, small bowel bacterial overgrowth, and metabolic bone disease.  In rare cases, food that is poorly digested can collect in the stomach and form a bezoar, a mass of undigested material that can cause a blockage in the gastrointestinal tract. Gastroparesis is more common in people with diabetes and those who have had recent stomach or intestinal surgery.  Other causes include infections, hormonal disorders like hypothyroidism, connective tissue disorders like scleroderma, autoimmune conditions, neuromuscular diseases, psychological conditions, and eating disorders. In some cases, the cause is not known (idiopathic). Diagnosis is made on the basis of a radiographic gastric emptying test. Treatment may include dietary modifications such as adjusting the timing and size of meals, consuming more liquid-based meals, or avoiding foods that are more difficult to digest (such as fatty foods, or foods with too much fiber). Other treatments may include endoscopic procedures to break the bezoar apart and remove it, feeding tubes, surgery, placement of an electrical stimulator, and medication such as metoclopramide, domperidone, erythromycin and cisapride.  With proper management many people with gastroparesis can live a relatively normal life. However, others may not tolerate treatment and may experience significant complications, a decreased quality of life, and reduced survival.

MalaCards based summary : Gastroparesis, also known as delayed gastric emptying, is related to stomach disease and dyspepsia, and has symptoms including ophthalmoplegia, hemiplegia and signs and symptoms, digestive. An important gene associated with Gastroparesis is MLN (Motilin), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Prucalopride and Domperidone have been mentioned in the context of this disorder. Affiliated tissues include testes, small intestine and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Gastroparesis (GP also called delayed gastric emptying) is a medical condition consisting of a paresis... more...

Sources

Related Diseases for Gastroparesis

About this section

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 166)
# Related Disease Score Top Affiliating Genes
1 stomach disease 31.7 GAST GHRL MLN
2 dyspepsia 30.3 CCK GHRL HTR3A
3 pylorospasm 30.0 GAST GHRL MLN
4 duodenogastric reflux 29.7 CCK GAST MLN
5 gastroesophageal reflux 29.7 CCK GAST GHRL MLN
6 constipation 29.5 CCK GAST HTR3A MLN MLNR
7 bulimia nervosa 29.4 CCK GHRL HTR3A
8 irritable bowel syndrome 29.4 CCK HTR3A MLN
9 diarrhea 29.3 ABCB1 CCK GAST HTR3A
10 parkinson disease, late-onset 29.2 CYP2D6 DRD2 HMOX1 NOS1
11 body mass index quantitative trait locus 11 28.7 CCK DRD2 GHRL GHSR HMOX1
12 brittle diabetes 11.1
13 diabetes mellitus 10.4
14 galactorrhea 10.3 CYP2D6 DRD2
15 codeine toxicity 10.3 ABCB1 CYP2D6
16 delusional disorder 10.3 CYP2D6 DRD2
17 tardive dyskinesia 10.3 CYP2D6 DRD2
18 helicobacter pylori infection 10.3
19 neuropathy 10.3
20 functional colonic disease 10.3 MLN MLNR
21 neuroleptic malignant syndrome 10.2 CYP2D6 DRD2
22 colonic pseudo-obstruction 10.2 MLN MLNR
23 anorexia nervosa 10.2
24 atrial fibrillation 10.2
25 opioid abuse 10.2 CCK DRD2
26 paralytic ileus 10.1 ABCB1 CCK
27 blind loop syndrome 10.1 GHRL MLN
28 non-functioning pancreatic endocrine tumor 10.1 GAST GHRL
29 nasal cavity adenocarcinoma 10.1 CCK GAST
30 autonomic neuropathy 10.1
31 pancreatic cholera 10.1 CCK GAST
32 duodenal gastrinoma 10.1 CCK GAST
33 multiple sclerosis 10.1
34 small cell cancer of the lung 10.1
35 achalasia 10.1
36 postcholecystectomy syndrome 10.0 CCK GAST MLN
37 opioid addiction 10.0 ABCB1 CCK DRD2
38 space motion sickness 10.0 CCK GAST MLN
39 celiac disease 1 10.0
40 diabetes mellitus, insulin-dependent 10.0
41 meconium ileus 10.0
42 duodenal ulcer 10.0
43 pneumonia 10.0
44 disease of mental health 10.0 CCK CYP2D6 DRD2
45 pancreatic steatorrhea 10.0 CCK GHRL
46 autoimmune disease of gastrointestinal tract 10.0 CYP2D6 GAST
47 lung cancer 10.0
48 cystic fibrosis 10.0
49 pancreatic cancer 10.0
50 demyelinating disease 10.0

Graphical network of the top 20 diseases related to Gastroparesis:



Diseases related to Gastroparesis
Sources

Symptoms & Phenotypes for Gastroparesis

About this section

UMLS symptoms related to Gastroparesis:


ophthalmoplegia, hemiplegia, signs and symptoms, digestive, lassitude, persistent vomiting

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.32 GHSR HTR3A MLN
2 Decreased viability GR00381-A-2 9.32 GHSR
3 Decreased viability GR00381-A-3 9.32 GHSR HTR3A MLN
4 Decreased viability GR00402-S-2 9.32 GHSR HTR3A MLN

MGI Mouse Phenotypes related to Gastroparesis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 ABCB1 DRD2 GHRL GHSR HMOX1 HTR3A
2 adipose tissue MP:0005375 9.72 DRD2 GHRL GHSR HMOX1 NOS1
3 digestive/alimentary MP:0005381 9.63 ABCB1 DRD2 GAST GHRL GHSR NOS1
4 endocrine/exocrine gland MP:0005379 9.56 ABCB1 CCK DRD2 GAST GHRL HMOX1
5 homeostasis/metabolism MP:0005376 9.32 ABCB1 CCK DRD2 GAST GHRL GHSR
Sources

Drugs & Therapeutics for Gastroparesis

About this section

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 249)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prucalopride Approved Phase 4,Phase 2,Phase 3 179474-81-8
2
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 57808-66-9 3151
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
4
Sodium Citrate Approved, Investigational Phase 4,Not Applicable 68-04-2
5
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
6
Ticagrelor Approved Phase 4 274693-27-5 9871419
7
Glucagon Approved Phase 4 16941-32-5
8
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53608-75-6
9
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
10
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
11
Carbidopa Approved Phase 4 28860-95-9 34359
12
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
13
Levodopa Approved Phase 4,Phase 2,Not Applicable 59-92-7 6047
14
Esomeprazole Approved, Investigational Phase 4,Not Applicable 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
15
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2 50-03-3
16
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754
17
Tadalafil Approved, Investigational Phase 4,Phase 2 171596-29-5 110635
18
Thrombin Approved, Investigational Phase 4
19
Pasireotide Approved Phase 4 396091-73-9 9941444
20
Haloperidol Approved Phase 4 52-86-8 3559
21
Exenatide Approved, Investigational Phase 4,Phase 1,Phase 2 141758-74-9 15991534
22
Calcium Approved, Nutraceutical Phase 4,Not Applicable 7440-70-2 271
23
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
24 Mosapride Investigational Phase 4,Not Applicable 112885-41-3
25 Serotonin Receptor Agonists Phase 4,Phase 2,Phase 3,Not Applicable
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
28 Laxatives Phase 4,Phase 2,Phase 3
29 Cathartics Phase 4,Phase 2,Phase 3
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Anticoagulants Phase 4,Not Applicable
33 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Calcium, Dietary Phase 4,Not Applicable
35 Citrate Phase 4,Not Applicable
36 Chelating Agents Phase 4,Not Applicable
37 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Antipyretics Phase 4
41 Analgesics Phase 4,Phase 2
42 Analgesics, Non-Narcotic Phase 4
43 Glucagon-Like Peptide 1 Phase 4
44 Hemostatics Phase 4,Not Applicable
45 Fibrin Tissue Adhesive Phase 4,Phase 3,Not Applicable
46 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Coagulants Phase 4,Not Applicable
48 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 Hormones Phase 4,Phase 1,Phase 2,Not Applicable
50 Incretins Phase 4,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 303)
# Name Status NCT ID Phase Drugs
1 Prucalopride Versus Placebo in Gastroparesis Unknown status NCT02510976 Phase 4 prucalopride;placebo
2 Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis Unknown status NCT02264587 Phase 4 Mosapride;domperidone
3 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Unknown status NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
4 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
5 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis Completed NCT00492622 Phase 4 Immediate-release omeprazole;Delayed-release omeprazole
6 Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
7 Gastric Functions & Proton Pump Inhibitor( PPI) Study Completed NCT00951431 Phase 4 Esomeprazole;Placebo
8 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
9 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
10 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Active, not recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
11 An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
12 An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus Terminated NCT01286090 Phase 4 Cisapride;Placebo
13 Haloperidol vs Conventional Therapy for Gastroparesis Terminated NCT02057549 Phase 4 Haloperidol;Conventional Therapy
14 Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis Terminated NCT00390975 Phase 4 Tegaserod
15 Enterra Therapy Gastric Stimulation System Terminated NCT00556166 Phase 4
16 An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects Terminated NCT02793154 Phase 4 Exenatide;Albiglutide
17 Gastric vs Jejunal Feeding in Diabetic Gastroparesis Withdrawn NCT00944593 Phase 4
18 Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis Withdrawn NCT01326117 Phase 4 tadalafil
19 Sancuso® for Gastroparesis: An Open Label Study. Unknown status NCT01989221 Phase 3 Sancuso®
20 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
21 A Prospective Randomized Controlled Multicenter Trial of Delayed Gastric Emptying (DGE) After Pancreaticoduodenectomy Evaluating by Gastrointestinal Reconstruction Unknown status NCT01460550 Phase 3
22 Nortriptyline for Idiopathic Gastroparesis Completed NCT00765895 Phase 3 Nortriptyline Hydrochloride;Placebo (for nortriptyline)
23 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Completed NCT02025725 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
24 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis Completed NCT02025751 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
25 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
26 Prucalopride Versus Placebo in Gastroparesis Completed NCT02031081 Phase 2, Phase 3 Prucalopride;Placebo
27 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial Completed NCT01149369 Phase 3 Aprepitant;Placebo
28 Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility Completed NCT01379183 Phase 2, Phase 3 Erythromycin;Placebo
29 Standardization of Surgery on the Pancreatic Cancer Completed NCT00679913 Phase 3
30 Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy Completed NCT01544790 Phase 3
31 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 Recruiting NCT03383146 Phase 3 Relamorelin;Placebo
32 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Recruiting NCT03285308 Phase 3 Relamorelin;Placebo
33 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02 Recruiting NCT03426345 Phase 3 Relamorelin;Placebo
34 Diabetic Gastroparesis Study 05 Recruiting NCT03786380 Phase 3 Relamorelin 10 μg
35 Domperidone in Treating Patients With Gastrointestinal Disorders Recruiting NCT01696734 Phase 3 Domperidone
36 REinforcement of the Pancreas in distaL pAncreatectomY (REPLAY) Recruiting NCT03030170 Phase 3
37 Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy Recruiting NCT03398291 Phase 3 Standard chemotherapy
38 Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve Recruiting NCT02524626 Phase 3
39 Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy Active, not recruiting NCT02457156 Phase 3 Octreotide
40 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 Enrolling by invitation NCT03420781 Phase 3 Relamorelin;Placebo
41 PoLyglycolic Acid Felt reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial) Enrolling by invitation NCT03331718 Phase 3 PGA felt reinforcement
42 Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy Not yet recruiting NCT02927886 Phase 3
43 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer Not yet recruiting NCT03317886 Phase 3
44 Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy Not yet recruiting NCT03419676 Phase 3
45 Acupuncture for Diabetic Gastroparesis Suspended NCT00470795 Phase 3
46 Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus Terminated NCT00228891 Phase 2, Phase 3
47 The Use of Domperidone for Gastroparesis Withdrawn NCT01378884 Phase 3 Domperidone
48 Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy Withdrawn NCT00622804 Phase 3
49 Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes Withdrawn NCT00228904 Phase 2, Phase 3
50 Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People Unknown status NCT02308254 Phase 1, Phase 2 Lixisenatide;Placebo

Search NIH Clinical Center for Gastroparesis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: gastroparesis

Sources

Genetic Tests for Gastroparesis

About this section

Genetic tests related to Gastroparesis:

# Genetic test Affiliating Genes
1 Gastroparesis 30
Sources

Anatomical Context for Gastroparesis

About this section

MalaCards organs/tissues related to Gastroparesis:

42
Testes, Small Intestine, Bone, Pancreas, Lung, Colon, Liver
Sources

Publications for Gastroparesis

About this section

Articles related to Gastroparesis:

(show top 50) (show all 1582)
# Title Authors Year
1
Gastric peroral endoscopic myotomy for transthyretin amyloidosis gastroparesis. ( 30791050 )
2019
2
High Prevalence of Slow Transit Constipation in Patients With Gastroparesis. ( 30870880 )
2019
3
Prevalence and severity of symptoms suggestive of gastroparesis in prodromal dementia with Lewy bodies. ( 30901488 )
2019
4
Gastroparesis and Functional Dyspepsia: A Blurring Distinction of Pathophysiology and Treatment. ( 30509017 )
2019
5
Gastroparesis Versus Functional Dyspepsia: Still Running on Emptying. ( 30725286 )
2019
6
Sarcina Organisms: A Potential Cause of Emphysematous Gastritis in a Patient With Gastroparesis. ( 30848737 )
2019
7
Epidemiology and Pathophysiology of Gastroparesis. ( 30396519 )
2019
8
Stent Placement for the Treatment of Gastroparesis. ( 30396520 )
2019
9
Diabetic Gastroparesis and Nondiabetic Gastroparesis. ( 30396524 )
2019
10
Clinical Manifestation and Natural History of Gastroparesis. ( 30396526 )
2019
11
Evaluation of Patients with Suspected Gastroparesis. ( 30396527 )
2019
12
Symptomatic Management of Gastroparesis. ( 30396528 )
2019
13
Gastric Electrical Stimulator for Treatment of Gastroparesis. ( 30396529 )
2019
14
Surgical Management for Gastroparesis. ( 30396530 )
2019
15
Botulinum Toxin Injection for Treatment of Gastroparesis. ( 30396531 )
2019
16
Gastroparesis: New Approaches in Management. ( 30396532 )
2019
17
Gastroparesis: Current Opinions and New Endoscopic Therapies. ( 30396533 )
2019
18
Helping Patients with Gastroparesis. ( 30466677 )
2019
19
The willingness of patients with gastroparesis to take risks with medications. ( 30628106 )
2019
20
Pathophysiology of idiopathic gastroparesis and implications for therapy. ( 30638082 )
2019
21
Association between duration or etiology of gastroparesis and clinical response after gastric per-oral endoscopic pyloromyotomy. ( 30653937 )
2019
22
Gastroparesis syndromes: Response to electrical stimulation. ( 30706646 )
2019
23
The American neurogastroenterology and motility society gastroparesis cardinal symptom index-daily diary (ANMS GCSI-DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis. ( 30734412 )
2019
24
A comparison of the diagnosis of gastroparesis in 4 h pediatric gastric emptying studies versus 2 h studies. ( 30744574 )
2019
25
Reflux Symptoms in Gastroparesis: Correlation With Gastroparesis Symptoms, Gastric Emptying, and Esophageal Function Testing. ( 30762609 )
2019
26
Is gastroparesis a gastric disease? ( 30773743 )
2019
27
Gastric peroral endoscopic pyloromyotomy for refractory diabetic gastroparesis: First case report in Taiwan. ( 30808584 )
2019
28
Per-Oral Pyloromyotomy (POP) for Medically Refractory Post-Surgical Gastroparesis. ( 30809781 )
2019
29
Therapeutic effect of a temporary transpyloric stent in refractory post-surgical gastroparesis: a case report. ( 30813940 )
2019
30
Outcomes of per oral endoscopic pyloromyotomy in gastroparesis worldwide. ( 30833798 )
2019
31
Efficacy and feasibility of G-POEM in management of patients with refractory gastroparesis: a systematic review and meta-analysis. ( 30842971 )
2019
32
Abdominal Pain in Patients with Gastroparesis: Associations with Gastroparesis Symptoms, Etiology of Gastroparesis, Gastric Emptying, Somatization, and Quality of Life. ( 30852767 )
2019
33
Statins and Abnormal Liver Enzymes. ( 30855731 )
2019
34
Development and psychometric evaluation of the Diabetic Gastroparesis Symptom Severity Diary. ( 30863134 )
2019
35
Cannabinoid Use in Patients With Gastroparesis and Related Disorders: Prevalence and Benefit. ( 30865015 )
2019
36
Activation of Nrf2 attenuates delayed gastric emptying in obesity induced diabetic (T2DM) female mice. ( 30831189 )
2019
37
Nausea and Vomiting in a Diabetic Patient with Delayed Gastric Emptying: Do not Delay Diagnosis. ( 30673987 )
2019
38
Risk factors for post-pancreaticoduodenectomy delayed gastric emptying in the absence of pancreatic fistula or intra-abdominal infection. ( 30737792 )
2019
39
Influencing factors of postoperative early delayed gastric emptying after minimally invasive Ivor-Lewis esophagectomy. ( 30746370 )
2019
40
Effects of antecolic versus retrocolic duodenojejunostomy on delayed gastric emptying after pyloric preserving pancreaticoduodenectomy in patients with periampullary tumors. ( 30792049 )
2019
41
Dual loop (Roux en Y) reconstruction with isolated gastric limb reduces delayed gastric emptying after pancreatico-duodenectomy. ( 30842815 )
2019
42
Glycosylated hemoglobin level may predict the severity of gastroparesis in diabetic patients. ( 29111279 )
2018
43
G-POEM for Gastroparesis: Is There Pressure to Go with the Flow? ( 29855769 )
2018
44
Rome IV Diagnostic Questionnaire Complements Patient Assessment of Gastrointestinal Symptoms for Patients with Gastroparesis Symptoms. ( 29808246 )
2018
45
The effect of extracorporeal low-energy shockwave on diabetic gastroparesis in a rat model. ( 29966170 )
2018
46
Pyloric sphincter characteristics using EndoFLIP<sup>Ar</sup> in gastroparesis. ( 29709494 )
2018
47
Delivery of Mesenchymal Stem Cells from Gelatin-Alginate Hydrogels to Stomach Lumen for Treatment of Gastroparesis. ( 29414870 )
2018
48
A Critical Review of the Current Clinical Landscape of Gastroparesis. ( 29928159 )
2018
49
LncRNA MALAT1 is up-regulated in diabetic gastroparesis and involved in high-glucose-induced cellular processes in human gastric smooth muscle cells. ( 29317209 )
2018
50
Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. ( 29111115 )
2018
Sources

Variations for Gastroparesis

About this section
Sources

Expression for Gastroparesis

About this section
Search GEO for disease gene expression data for Gastroparesis.
Sources

Pathways for Gastroparesis

About this section

Pathways related to Gastroparesis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 67
Show member pathways
 13.02 CCK DRD2 GHRL GHSR MLN MLNR
2
cAMP signaling pathway 38
11.66 DRD2 GHRL GHSR
3
Doxorubicin Pathway, Pharmacokinetics 62
Show member pathways
 10.92 ABCB1 NOS1
4
Ondansetron Pathway, Pharmacokinetics/Pharmacodynamics 62
Show member pathways
 10.16 CYP2D6 HTR3A
5
Gastric acid production 1
9.47 CCK GAST
Sources

GO Terms for Gastroparesis

About this section

Cellular components related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.26 CCK DRD2 GHRL HTR3A
2 glutamatergic synapse GO:0098978 8.92 DRD2 GHRL GHSR HTR3A

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.93 CCK GAST GHRL MLN
2 response to hypoxia GO:0001666 9.82 DRD2 HMOX1 NOS1
3 G protein-coupled receptor signaling pathway GO:0007186 9.8 CCK DRD2 GAST GHRL GHSR MLN
4 excitatory postsynaptic potential GO:0060079 9.72 DRD2 GHRL HTR3A
5 response to hormone GO:0009725 9.69 GHRL GHSR NOS1
6 response to cocaine GO:0042220 9.67 DRD2 HTR3A
7 response to nicotine GO:0035094 9.66 DRD2 HMOX1
8 negative regulation of blood pressure GO:0045776 9.65 DRD2 NOS1
9 positive regulation of sprouting angiogenesis GO:1903672 9.65 GHRL GHSR
10 exogenous drug catabolic process GO:0042738 9.64 CYP2D6 NOS1
11 decidualization GO:0046697 9.64 GHRL GHSR
12 positive regulation of vascular endothelial cell proliferation GO:1905564 9.63 GHRL GHSR
13 response to food GO:0032094 9.62 GAST GHSR
14 regulation of postsynapse organization GO:0099175 9.62 GHRL GHSR
15 regulation of sodium ion transport GO:0002028 9.61 DRD2 NOS1
16 actin polymerization or depolymerization GO:0008154 9.61 GHRL GHSR
17 positive regulation of growth GO:0045927 9.6 GHRL GHSR
18 adult feeding behavior GO:0008343 9.59 GHRL GHSR
19 negative regulation of interleukin-1 beta production GO:0032691 9.58 GHRL GHSR
20 negative regulation of appetite GO:0032099 9.58 CCK GHSR
21 positive regulation of growth hormone secretion GO:0060124 9.57 DRD2 GHRL
22 negative regulation of tumor necrosis factor secretion GO:1904468 9.56 GHRL GHSR
23 growth hormone secretion GO:0030252 9.54 GHRL GHSR
24 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.52 GHRL GHSR
25 positive regulation of multicellular organism growth GO:0040018 9.5 DRD2 GHRL GHSR
26 negative regulation of interleukin-6 biosynthetic process GO:0045409 9.49 GHRL GHSR
27 positive regulation of appetite GO:0032100 9.48 GHRL GHSR
28 positive regulation of eating behavior GO:1904000 9.46 GHRL GHSR
29 regulation of transmission of nerve impulse GO:0051969 9.43 GHRL GHSR
30 positive regulation of small intestine smooth muscle contraction GO:1904349 9.4 GHRL GHSR
31 regulation of gastric motility GO:1905333 9.37 GHRL GHSR
32 positive regulation of small intestinal transit GO:0120058 9.16 GHRL GHSR
33 negative regulation of insulin secretion GO:0046676 9.13 DRD2 GHRL GHSR
34 postsynaptic modulation of chemical synaptic transmission GO:0099170 8.8 DRD2 GHRL GHSR
35 signal transduction GO:0007165 10.14 CCK DRD2 GAST GHSR HTR3A MLNR

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.33 CYP2D6 HMOX1 NOS1
2 hormone binding GO:0042562 8.96 GHSR MLNR
3 hormone activity GO:0005179 8.92 CCK GAST GHRL MLN
Sources

Sources for Gastroparesis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....